Burnham W R, Lennard-Jones J E, Hecketsweiler P, Colin R, Geffroy Y
Gut. 1979 Mar;20(3):229-33. doi: 10.1136/gut.20.3.229.
In a randomised double-blind trial over one year oral BCG has been compared with a control preparation in the treatment of chronic Crohn's disease. Overall assessment scores deteriorated in nine of 22 patients taking BCG, and 11 of 26 in the control group (P = 0.25); this deterioration was great enough to be regarded as a clinical relapse in three patients taking BCG and in seven taking the control preparation (P greater than 0.1). No significant benefit from oral BCG treatment has been demonstrated.
在一项为期一年的随机双盲试验中,对口服卡介苗与一种对照制剂治疗慢性克罗恩病的效果进行了比较。服用卡介苗的22名患者中有9名总体评估得分恶化,而对照组26名患者中有11名出现这种情况(P = 0.25);这种恶化严重到足以被视为3名服用卡介苗的患者和7名服用对照制剂的患者出现临床复发(P>0.1)。口服卡介苗治疗未显示出显著益处。